Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-GPRC5D CAR-T cells (920th Hospital)
- Development stage
- Unknown
- Lead developer
- People's Liberation Army
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
The anti-GPRC5D CAR-T therapy developed by the 920th Hospital of Joint Logistics Support Force is a second-generation chimeric antigen receptor (CAR) T-cell product designed to treat relapsed or refractory multiple myeloma. The construct features a humanized rabbit monoclonal antibody-derived single-chain variable fragment (scFv) targeting G protein-coupled receptor class C group 5 member D (GPRC5D), a protein highly expressed on malignant plasma cells. This scFv is linked to a 4-1BB costimulatory domain and a CD3ζ signaling domain to enhance T-cell activation and persistence. Clinical evaluation in investigator-initiated trials (NCT05739188) has demonstrated promising efficacy with high overall response rates and a manageable safety profile in patients who have failed prior lines of therapy.
- Other names
- anti-GPRC5D CAR-T cellsanti-GPRC-5D CAR-T cellsanti-GPRC 5D CAR-T cellsGPRC5D-targeted CAR-T cellsGPRC-5D-targeted CAR-T cellsGPRC 5D-targeted CAR-T cells
02
Targets
GPRC5D
Beyond the preview
Go deeper on anti-GPRC5D CAR-T cells (920th Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-GPRC5D CAR-T cells (920th Hospital).